Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

RAHWAY, N.J.--(BUSINESS WIRE) August 25, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials